(Q48786818)

15 February 2018

title

Subcutaneous immunoglobulin in polymyositis and dermatomyositis: A novel application (English)

1 reference

https://api.crossref.org/works/10.1016/J.AUTREV.2010.09.004

17 July 2024

0 references

0 references

Maria Giovanna Danieli

1

object named as

Maria Giovanna Danieli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20858553

17 July 2024

author name string

Lucia Pettinari

2

1 reference

15 February 2018

Romina Moretti

3

1 reference

15 February 2018

Francesco Logullo

4

1 reference

15 February 2018

Armando Gabrielli

5

1 reference

15 February 2018

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20858553

17 July 2024

publication date

19 September 2010

1 reference

15 February 2018

full work available at URL

https://api.elsevier.com/content/article/PII:S1568997210002004?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.AUTREV.2010.09.004

https://api.elsevier.com/content/article/PII:S1568997210002004?httpAccept=text/plain

17 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.AUTREV.2010.09.004

17 July 2024

1 reference

15 February 2018

volume

10

1 reference

15 February 2018

issue

3

1 reference

15 February 2018

page(s)

144-149

1 reference

15 February 2018

Polymyositis and dermatomyositis (second of two parts)

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.AUTREV.2010.09.004

Immunotherapy of myositis: issues, concerns and future prospects

17 July 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.AUTREV.2010.09.004

A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis

17 July 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.AUTREV.2010.09.004

Guidelines on the use of intravenous immune globulin for neurologic conditions

17 July 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.AUTREV.2010.09.004

Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis

17 July 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.AUTREV.2010.09.004

Information for healthcare providers on general features of IGIV with emphasis on differences between commercially available products

17 July 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.AUTREV.2010.09.004

Subcutaneous administration of IgG.

17 July 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.AUTREV.2010.09.004

Interobserver agreement for the assessment of handicap in stroke patients.

17 July 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.AUTREV.2010.09.004

The electrodiagnostic examination with myopathies.

17 July 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.AUTREV.2010.09.004

The Italian SF-36 Health Survey: translation, validation and norming

17 July 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.AUTREV.2010.09.004

6th International Immunoglobulin Symposium: poster presentations

17 July 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.AUTREV.2010.09.004

Subcutaneous immunoglobulin administration: an alternative to intravenous infusion as adjuvant treatment for dermatomyositis?

17 July 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.AUTREV.2010.09.004

Intravenous immunoglobulin therapy for autoimmune diseases

17 July 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.AUTREV.2010.09.004

Evidence for the use of intravenous immunoglobulins--a review of the literature

17 July 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.AUTREV.2010.09.004

Role of natural antibodies in immune homeostasis: IVIg perspective.

17 July 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.AUTREV.2010.09.004

What is the contents of the magic draft IVIg?

17 July 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.AUTREV.2010.09.004

Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: implications for the clinical use of intravenous immunoglobulins (IVIg).

17 July 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.AUTREV.2010.09.004

Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome.

17 July 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.AUTREV.2010.09.004

Intravenous immunoglobulin - indications and mechanisms in cardiovascular diseases

17 July 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.AUTREV.2010.09.004

Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function.

17 July 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.AUTREV.2010.09.004

Role of regulatory T cells in a new mouse model of experimental autoimmune myositis

17 July 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.AUTREV.2010.09.004

Prospective study on CVID patients with adverse reactions to intravenous or subcutaneous IgG administration

17 July 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.AUTREV.2010.09.004

17 July 2024

Identifiers

1 reference

15 February 2018

1 reference

15 February 2018